AstraZeneca (LON:AZN) Rating Reiterated by Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by Shore Capital in a research note issued to investors on Monday, LSE.Co.UK reports.

AZN has been the topic of a number of other research reports. UBS Group dropped their target price on shares of AstraZeneca from £107 ($135.43) to GBX 9,900 ($125.30) and set a “sell” rating on the stock in a report on Monday, February 12th. BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a report on Monday, February 12th. Berenberg Bank restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, March 13th. Jefferies Financial Group restated a “hold” rating and set a £110 ($139.22) target price on shares of AstraZeneca in a report on Friday, February 16th. Finally, Barclays restated an “overweight” rating and set a £125 ($158.21) target price on shares of AstraZeneca in a report on Monday, April 8th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of £115.43 ($146.09).

AstraZeneca Trading Down 0.4 %

LON:AZN traded down GBX 40 ($0.51) during trading hours on Monday, hitting £110.24 ($139.53). The company had a trading volume of 1,154,244 shares, compared to its average volume of 2,211,943. The company has a market capitalization of £170.87 billion, a PE ratio of 3,638.28, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The stock has a 50-day moving average price of £103.22 and a 200 day moving average price of £104.24. AstraZeneca has a 52 week low of GBX 9,461 ($119.74) and a 52 week high of £123.92 ($156.84). The company has a debt-to-equity ratio of 75.70, a current ratio of 0.82 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.